Immunomedics — Proxy Contest (January 2017)
19 slides from Immunomedics's proxy contest presentation, Jan 30, 2017
Slide 1: Setting the Record Straight: Immunomedics is Acting in the Best Interests of All Stockholders
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 IMMUNOMEDICS, INC. Advanced Antibody - Based Therapeutics Oncology Autoimmune Diseases January 2017 Setting the Record Straight: Immunomedics is Actin
Slide 2: Important Additional Information / Forward Looking Statements
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Important Additional Information / Forward Looking Statements Important Additional Information Immunomedics , Inc. (the “Company”), its directors and
Slide 3: Setting the Record Straight on venBio's Presentation Filed on January 26, 2017
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Setting the Record Straight on venBio’s Presentation Filed on January 26, 2017 • In response to venBio’s presentation filed on January 26, 2017, which
Slide 4: Immunomedics' New Board Formed in Response to Stockholder Requests and is Truly Independent
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 4 Immunomedics’ New Board Formed in Response to Stockholder Requests and is Truly Independent • Immunomedics listened to its stockholders and understo
Slide 5: Right Process Underway, Being Overseen by a New Board with the Right Experience
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 5 Right Process Underway, Being Overseen by a New Board with the Right Experience • Independent third - party experts have conducted a full commercial
Slide 6: Right Process Underway, Being Overseen by a New Board with the Right Experience
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 6 Right Process Underway, Being Overseen by a New Board with the Right Experience • Dr . Geoffrey Cox has 30+ years of experience in senior management
Slide 7: Jason Aryeh: Ligand Pharmaceuticals track record
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 • Ligand Pharmaceuticals, Inc . (NASDAQ: LGND): – At request of activist hedge fund Third Point LLC, Mr. Aryeh became an advisor engaged to lead Ligan
Slide 8: Jason Aryeh: QLT Inc. track record
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 • QLT Inc. (formerly NASDAQ: QLTI) (formerly TSX: QLT) : – Thirty - five days after Mr. Aryeh became Chairman, QLT implemented a strategic repositioni
Slide 9: Jason Aryeh: Proven Track Record of Creating Value & Advocating for Stockholders' Interests
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Jason Aryeh : Proven Track Record of Creating Value & Advocating for Stockholders’ Interests • Aralez Pharmaceuticals (NASDAQ: ARLZ ): – Aralez is a n
Slide 10: Jason Aryeh: Proven Track Record of Creating Value & Advocating for Stockholders' Interests
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Jason Aryeh : Proven Track Record of Creating Value & Advocating for Stockholders’ Interests • Nabi Biopharmaceuticals (formerly NASDAQ: NABI): – Mr .
Slide 11: New Board is Acutely Focused on Expeditiously Maximizing Stockholder Value
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 11 New Board is Acutely Focused on Expeditiously Maximizing Stockholder Value INDEPENDENT DIRECTOR ROLE & RESPONSIBILITIES FOR IMMUNOMEDICS Jason Arye
Slide 12: IMMU-132 Data is Solid and Since ASCO 2016, Patient Results Continue to Improve
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 12 IMMU - 132 Data is Solid and Since ASCO 2016, Patient Results Continue to Improve • IMMU - 132 data in TNBC patients is solid – Phase 2 clinical da
Slide 13: Robust Pipeline, Strong Relationships and Solid Development Program
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 13 Robust Pipeline, Strong Relationships and Solid Development Program • Contrary to what venBio stated in its presentation: – Immunomedics has engage
Slide 14: Stockholder Support Evidenced by Increasing Value Upon Achieving Recent Milestones
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Stockholder Support Evidenced by Increasing Value Upon Achieving Recent Milestones 14 Immunomedics ’ stock has increased 116% since the announced hiri
Slide 15: Immunomedics Stock Appreciation vs. Industry Peer Group & Biotech Index
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Immunomedics Stock Appreciation vs. Industry Peer Group & Biotech Index Small / Mid Cap Biotech Oncology Peers Peer 1 - YR Stock Return ( Mean) ( as o
Slide 16: venBio's Plan is to Make a Plan
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 16 venBio’s Plan is to Make a Plan In venBio’s own words from Slides 28 and 30 of their presentation , their objectives are to: • “ Understand key ope
Slide 17: venBio's Other Misleading Assertions
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 17 venBio’s Other Misleading Assertions IMMUNOMEDICS STATEMENTS VENBIO ASSERTIONS THE FACTS • “ venBio’s demands for representation and unilateral vet
Slide 18: IMMU Stockholders Have a Clear Choice – Vote the WHITE Proxy Card
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 18 IMMU Stockholders Have a Clear Choice – Vote the WHITE Proxy Card x Imminent Phase 3 trial and clear path to accelerated approval of IMMU - 132 in
Slide 19: Vote the WHITE Proxy Card Today
0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 VOTE THE WHITE PROXY CARD TODAY Vote FOR all the Immunomedics director nominees If you have already voted for venBio on a gold proxy card, it is not t